IMMUNOHISTOCHEMICAL DETECTION OF P53 PROTEIN IN BORDERLINE AND MALIGNANT SEROUS OVARIAN-TUMORS

被引:57
作者
KLEMI, PJ
TAKAHASHI, S
JOENSUU, H
KIILHOLMA, P
NARIMATSU, E
MORI, M
机构
[1] SAPPORO MED COLL HOSP,DIV PATHOL,SAPPORO,JAPAN
[2] UNIV TURKU,CENT HOSP,DEPT ONCOL,SF-20520 TURKU 52,FINLAND
[3] UNIV TURKU,CENT HOSP,DEPT GYNECOL & OBSTET,SF-20520 TURKU 52,FINLAND
[4] SAPPORO MED COLL,DEPT PATHOL 2,SAPPORO,HOKKAIDO 060,JAPAN
关键词
OVARIAN CANCER; SEROUS OVARIAN TUMORS; BORDERLINE TUMOR; P53; TUMOR SUPPRESSOR GENE; FLOW CYTOMETRY; DNA PLOIDY; S-PHASE FRACTION;
D O I
10.1097/00004347-199407000-00006
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The p53 suppressor gene protein expression was studied with immunoperoxidase staining in 61 serous tumors of the ovary. Twenty four (53%) of the 45 histologically malignant tumors were positive for p53, whereas neither the six benign nor the 10 tumors of borderline malignancy showed positive staining, except for one borderline tumor with atypia and increased mitotic activity. Therefore, p53 immunostaining may have diagnostic value in discriminating between borderline and malignant serous ovarian tumors. Malignant ovarian tumors with negative staining for p53 were associated with a 67% 3-year crude survival rate as compared with only an 18% 3-year survival rate if p53 staining was positive (p = 0.002). In a multivariate analysis, the p53 staining was the most important prognostic factor, with a relative risk of 4.2 (95% confidence interval, 1.8-9.9) followed by the FIGO stage (2.1, 1.3-3.5). We conclude that immunohistochemical p53 suppressor gene protein expression analysis has both diagnostic and prognostic value.
引用
收藏
页码:228 / 233
页数:6
相关论文
共 36 条
[1]  
AURE JC, 1971, OBSTET GYNECOL, V37, P1
[2]  
BAKER SJ, 1990, CANCER RES, V50, P7717
[3]   CHROMOSOME-17 DELETIONS AND P53 GENE-MUTATIONS IN COLORECTAL CARCINOMAS [J].
BAKER, SJ ;
FEARON, ER ;
NIGRO, JM ;
HAMILTON, SR ;
PREISINGER, AC ;
JESSUP, JM ;
VANTUINEN, P ;
LEDBETTER, DH ;
BARKER, DF ;
NAKAMURA, Y ;
WHITE, R ;
VOGELSTEIN, B .
SCIENCE, 1989, 244 (4901) :217-221
[4]   MEASUREMENT OF S-PHASE FRACTIONS IN LYMPHOID-TISSUE COMPARING FRESH VERSUS PARAFFIN-EMBEDDED TISSUE AND 4',6'-DIAMIDINO-2 PHENYLINDOLE DIHYDROCHLORIDE VERSUS PROPIDIUM IODIDE STAINING [J].
CAMPLEJOHN, RS ;
MACARTNEY, JC ;
MORRIS, RW .
CYTOMETRY, 1989, 10 (04) :410-416
[5]   GENETIC-BASIS FOR P53 OVEREXPRESSION IN HUMAN BREAST-CANCER [J].
DAVIDOFF, AM ;
HUMPHREY, PA ;
IGLEHART, JD ;
MARKS, JR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (11) :5006-5010
[6]   P53 FUNCTIONS AS A CELL-CYCLE CONTROL PROTEIN IN OSTEOSARCOMAS [J].
DILLER, L ;
KASSEL, J ;
NELSON, CE ;
GRYKA, MA ;
LITWAK, G ;
GEBHARDT, M ;
BRESSAC, B ;
OZTURK, M ;
BAKER, SJ ;
VOGELSTEIN, B ;
FRIEND, SH .
MOLECULAR AND CELLULAR BIOLOGY, 1990, 10 (11) :5772-5781
[7]  
ECCLES DM, 1990, ONCOGENE, V5, P1599
[8]  
EHLEN T, 1990, ONCOGENE, V5, P219
[9]   ACTIVATING MUTATIONS FOR TRANSFORMATION BY P53 PRODUCE A GENE-PRODUCT THAT FORMS AN HSC70-P53 COMPLEX WITH AN ALTERED HALF-LIFE [J].
FINLAY, CA ;
HINDS, PW ;
TAN, TH ;
ELIYAHU, D ;
OREN, M ;
LEVINE, AJ .
MOLECULAR AND CELLULAR BIOLOGY, 1988, 8 (02) :531-539
[10]   ACTIVATING MUTATIONS IN P53 PRODUCE A COMMON CONFORMATIONAL EFFECT - A MONOCLONAL-ANTIBODY SPECIFIC FOR THE MUTANT FORM [J].
GANNON, JV ;
GREAVES, R ;
IGGO, R ;
LANE, DP .
EMBO JOURNAL, 1990, 9 (05) :1595-1602